<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03449251</url>
  </required_header>
  <id_info>
    <org_study_id>DEFINE (A094666)</org_study_id>
    <nct_id>NCT03449251</nct_id>
  </id_info>
  <brief_title>A Series of Pilot Studies to Evaluate the haemoDynamic and mEtabolic Effects oF apelIn aNd rElaxin</brief_title>
  <acronym>DEFINE</acronym>
  <official_title>A Series of Pilot Studies to Evaluate the Haemodynamic and Metabolic Effects of Apelin and Relaxin in Healthy Humans, Subjects With Increased Weight and Patients With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cambridge University Hospitals NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Cambridge</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>MedImmune LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Cambridge University Hospitals NHS Foundation Trust</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Type two diabetes mellitus (T2DM) is a common, long term metabolic disorder characterised by
      hyperglycaemia (high blood glucose) resulting from insulin resistance and relative insulin
      insufficiency. The risk of developing insulin resistance and subsequently T2DM is increased
      by being overweight and also through a sedentary lifestyle. As the onset can be gradual,
      physiological damage may have occurred prior to diagnosis. Diabetes is associated with the
      development of microvascular complications (diabetic nephropathy, neuropathy, and
      retinopathy), and macrovascular complications (coronary artery disease, peripheral arterial
      disease, and stroke). While there are many treatments available for T2DM, these complications
      may still arise, leading to significant morbidity and mortality. There is therefore an urgent
      need to identify novel signalling pathways that may contribute to the development of diabetes
      related complications. The identification of these pathways may ultimately lead to the
      development of new therapies targeting better blood glucose control and preventing these
      subsequent complications.

      Both animal and human studies have indicated that two endogenous peptides, apelin and relaxin
      both act as vasodilators in the human cardiovascular system and could also have beneficial
      action in T2DM. Therefore, we aim to carry out experimental medicine studies to test this
      hypothesis, and explore the signalling pathway in the human vascular system.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An extensive body of evidence demonstrates a direct association between T2DM and
      cardiovascular complications and mortality. Unfortunately, current therapies for diabetes
      have failed to be translated into improvements in cardiovascular outcomes, highlighting an
      urgent need to develop novel therapeutic strategies that can ultimately achieve the dual
      outcome of improving glycaemic control and improving cardiovascular function.

      While the precise cellular mechanisms involved remain to be elucidated, we hypothesise that
      the apelin and relaxin pathways meet these two criteria and therefore are potential
      therapeutic targets in conditions of abnormal glucose metabolism and heart failure.

      Apelin and relaxin are safe for parenteral use as they are naturally occurring peptide
      hormones, have a short half-life and will be rapidly cleared. They target endogenous
      receptors and post-receptor signalling, and have been used in human trials without any
      significant side effects reported.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 28, 2018</start_date>
  <completion_date type="Anticipated">February 2020</completion_date>
  <primary_completion_date type="Anticipated">February 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
    <masking_description>Identical, colourless solution</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Sub-study 1a: Changes in markers of glucose homeostasis in healthy participants after infusion of apelin</measure>
    <time_frame>Visit 2 to visit 4, over a period of up to 8 weeks</time_frame>
    <description>Glucose, in mmol/l</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sub-study 1a: Changes in markers of glucose homeostasis in healthy participants after infusion of apelin</measure>
    <time_frame>Visit 2 to visit 4, over a period of up to 8 weeks</time_frame>
    <description>C-peptide, in pmol/L</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sub-study 1a: Changes in markers of glucose homeostasis in healthy participants after infusion of apelin</measure>
    <time_frame>Visit 2 to visit 4, over a period of up to 8 weeks</time_frame>
    <description>glucagon, in pg/ml</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sub-study 1a: Changes in markers of glucose homeostasis in healthy participants after infusion of apelin</measure>
    <time_frame>Visit 2 to visit 4, over a period of up to 8 weeks</time_frame>
    <description>insulin, in pmol/L</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sub-study 1a: Changes in markers of glucose homeostasis in healthy participants after infusion of apelin</measure>
    <time_frame>Visit 2 to visit 4, over a period of up to 8 weeks</time_frame>
    <description>TNF-alpha, in pg/ml</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sub-study 1b: Changes in markers of glucose homeostasis in participants with increased weight and participants with type 2 diabetes mellitus after infusion of apelin with or without mixed meal tolerance in obese/overweight and T2DM participants</measure>
    <time_frame>VIsit 2 to visit 5, over a period of up to 14 weeks</time_frame>
    <description>Glucose, in mmol/l</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sub-study 1b: Changes in markers of glucose homeostasis in participants with increased weight and participants with type 2 diabetes mellitus after infusion of apelin with or without mixed meal tolerance in obese/overweight and T2DM participants</measure>
    <time_frame>Visit 2 to visit 5, over a period of up to 14 weeks</time_frame>
    <description>C-peptide, in pmol/L</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sub-study 1b: Changes in markers of glucose homeostasis in participants with increased weight and participants with type 2 diabetes mellitus after infusion of apelin with or without mixed meal tolerance in obese/overweight and T2DM participants</measure>
    <time_frame>VIsit 2 to visit 5, over a period of up to 14 weeks</time_frame>
    <description>glucagon, , in pg/ml</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sub-study 1b: Changes in markers of glucose homeostasis in participants with increased weight and participants with type 2 diabetes mellitus after infusion of apelin with or without mixed meal tolerance in obese/overweight and T2DM participants</measure>
    <time_frame>Visit 2 to visit 5, over a period of up to 14 weeks</time_frame>
    <description>insulin, in pmol/L</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sub-study 1b: Changes in markers of glucose homeostasis in participants with increased weight and participants with type 2 diabetes mellitus after infusion of apelin with or without mixed meal tolerance in obese/overweight and T2DM participants</measure>
    <time_frame>Visit 2 to visit 5, over a period of up to 14 weeks</time_frame>
    <description>TNF-alpha, in pg/ml</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sub-study 2a: Change in forearm blood flow parameters in healthy participants after infusion of relaxin</measure>
    <time_frame>Within visit 2, over a period of up to 4 weeks</time_frame>
    <description>Absolute flow in the infused arm, in mg/dL/min</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sub-study 2a: Change in forearm blood flow parameters in healthy participants after infusion of relaxin</measure>
    <time_frame>Within visit 2, over a period of up to 4 weeks</time_frame>
    <description>Percentage change in the infused arm, in %</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sub-study 2a: Change in forearm blood flow parameters in healthy participants after infusion of relaxin</measure>
    <time_frame>Within visit 2, over a period of up to 4 weeks</time_frame>
    <description>Ratio, expressed as a number (no units as this is a ratio)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sub-study 2b: Change in forearm blood flow parameters in healthy participants after infusion of relaxin in the presence of L-NMMA or normal saline</measure>
    <time_frame>Visit 2 to visit 3, over a period of up to 10 weeks</time_frame>
    <description>Ratio; absolute flow and percentage change in the infused arm</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sub-study 2b: Change in forearm blood flow parameters in health participants after infusion of verapamil in the presence of L-NMMA or normal saline</measure>
    <time_frame>Visit 2 to visit 3, over a period of up to 10 weeks</time_frame>
    <description>Ratio; expressed as a number (no units as this is a ratio)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sub-study 2b: Change in forearm blood flow parameters in health participants after infusion of verapamil in the presence of L-NMMA or normal saline</measure>
    <time_frame>Visit 2 to visit 3, over a period of up to 10 weeks</time_frame>
    <description>absolute flow in the infused arm, in mg/dL/min</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sub-study 2b: Change in forearm blood flow parameters in health participants after infusion of verapamil in the presence of L-NMMA or normal saline</measure>
    <time_frame>Visit 2 to visit 3, over a period of up to 10 weeks</time_frame>
    <description>percentage change in the infused arm, In %</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sub-Study 3a: Change in forearm blood flow parameters in healthy participants after incremental infusions of intra-arterial relaxin in the presence of apelin</measure>
    <time_frame>Visit 2 to visit 3, over a period of up to 10 weeks</time_frame>
    <description>Ratio; absolute flow and percentage change in the infused arm</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sub-Study 3a: Change in forearm blood flow parameters in healthy participants after incremental infusions of intra-arterial relaxin in the presence of apelin</measure>
    <time_frame>Visit 2 to visit 3, over a period of up to 10 weeks</time_frame>
    <description>Ratio, expressed as a number (no units as this is a ratio)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sub-Study 3a: Change in forearm blood flow parameters in healthy participants after incremental infusions of intra-arterial relaxin in the presence of apelin</measure>
    <time_frame>Visit 2 to visit 3, over a period of up to 10 weeks</time_frame>
    <description>absolute flow in the infused arm, in mg/dL/min</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sub-Study 3a: Change in forearm blood flow parameters in healthy participants after incremental infusions of intra-arterial relaxin in the presence of apelin</measure>
    <time_frame>Visit 2 to visit 3, over a period of up to 10 weeks</time_frame>
    <description>percentage change in the infused arm, In %</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sub-Study 3b: Change in forearm blood flow parameters in healthy participants after incremental infusions of intra-arterial apelin in the presence of relaxin</measure>
    <time_frame>Visit 2 to visit 3, over a period of up to 10 weeks</time_frame>
    <description>Ratio, expressed as a number (no units as this is a ratio)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sub-Study 3b: Change in forearm blood flow parameters in healthy participants after incremental infusions of intra-arterial apelin in the presence of relaxin</measure>
    <time_frame>Visit 2 to visit 3, over a period of up to 10 weeks</time_frame>
    <description>absolute flow in the infused arm, in mg/dL/min</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sub-Study 3b: Change in forearm blood flow parameters in healthy participants after incremental infusions of intra-arterial apelin in the presence of relaxin</measure>
    <time_frame>Visit 2 to visit 3, over a period of up to 10 weeks</time_frame>
    <description>percentage change in the infused arm, In %</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sub-study 4: Changes in markers of glucose homeostasis healthy participants, participants with increased weight and participants with type 2 diabetes mellitus after infusion of relaxin with and without apelin</measure>
    <time_frame>Visit 2 to Visit 4, over a period of up to 8 weeks</time_frame>
    <description>glucose, in each of the groups, in mmol/L</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sub-study 4: Changes in markers of glucose homeostasis healthy participants, participants with increased weight and participants with type 2 diabetes mellitus after infusion of relaxin with and without apelin</measure>
    <time_frame>Visit 2 to Visit 4, over a period of up to 8 weeks</time_frame>
    <description>C-peptide, in each of the groups, in pmol/L</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sub-study 4: Changes in markers of glucose homeostasis healthy participants, participants with increased weight and participants with type 2 diabetes mellitus after infusion of relaxin with and without apelin</measure>
    <time_frame>Visit 2 to Visit 4, over a period of up to 8 weeks</time_frame>
    <description>glucagon, in each of the groups,in pg/ml</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sub-study 4: Changes in markers of glucose homeostasis healthy participants, participants with increased weight and participants with type 2 diabetes mellitus after infusion of relaxin with and without apelin</measure>
    <time_frame>Visit 2 to Visit 4, over a period of up to 8 weeks</time_frame>
    <description>insulin, in each of the groups,in pmol/L</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sub-study 4: Changes in markers of glucose homeostasis healthy participants, participants with increased weight and participants with type 2 diabetes mellitus after infusion of relaxin with and without apelin</measure>
    <time_frame>Visit 2 to Visit 4, over a period of up to 8 weeks</time_frame>
    <description>TNF-alpha, in each of the groups, in pg/ml</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sub-study 1a: Changes in parameters of cardiovascular haemodynamics in healthy participants after infusion of apelin</measure>
    <time_frame>Visit 2 to visit 4, over a period of up to 8 weeks</time_frame>
    <description>Cardiac output measured by Echocardiography, in L/min</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sub-study 1a: Changes in parameters of cardiovascular haemodynamics in healthy participants after infusion of apelin</measure>
    <time_frame>Visit 2 to visit 4, over a period of up to 8 weeks</time_frame>
    <description>cardiac output measured by Innocor , in L/min</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sub-study 1a: Changes in parameters of cardiovascular haemodynamics in healthy participants after infusion of apelin</measure>
    <time_frame>VIsit 2 to visit 4, over a period of up to 8 weeks</time_frame>
    <description>Cardiac output measured by bioimpedance, in L/min</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sub-study 1b: Changes in parameters of cardiovascular haemodynamics in obese/overweight and T2DM participants after infusion of apelin</measure>
    <time_frame>VIsit 2 to visit 4, over a period of up to 8 weeks</time_frame>
    <description>Cardiac output measured by Echocardiography, in L/min</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sub-study 1b: Changes in parameters of cardiovascular haemodynamics in obese/overweight and T2DM participants after infusion of apelin</measure>
    <time_frame>VIsit 2 to visit 4, over a period of up to 8 weeks</time_frame>
    <description>cardiac output measured by Innocor , in L/min</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sub-study 1b: Changes in parameters of cardiovascular haemodynamics in obese/overweight and T2DM participants after infusion of apelin</measure>
    <time_frame>VIsit 2 to visit 4, over a period of up to 8 weeks</time_frame>
    <description>Cardiac output measured by bioimpedance, in L/min</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sub-study 1b: Changes in parameters of cardiovascular haemodynamics in obese/overweight and T2DM participants after infusion of apelin,after a mixed meal challenge</measure>
    <time_frame>VIsit 2 to visit 4, over a period of up to 8 weeks</time_frame>
    <description>Cardiac output measured by Echocardiography, in L/min</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sub-study 1b: Changes in parameters of cardiovascular haemodynamics in obese/overweight and T2DM participants after infusion of apelin, after a mixed meal challenge</measure>
    <time_frame>VIsit 2 to visit 4, over a period of up to 8 weeks</time_frame>
    <description>cardiac output measured by Innocor , in L/min</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sub-study 1b: Changes in parameters of cardiovascular haemodynamics in obese/overweight and T2DM participants after infusion of apelin,after a mixed meal challenge</measure>
    <time_frame>VIsit 2 to visit 4, over a period of up to 8 weeks</time_frame>
    <description>Cardiac output measured by bioimpedance, in L/min</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sub-study 1b: Changes in markers of glucose homeostasis after infusion of apelin in obese/overweight and T2DM, after a mixed meal challenge</measure>
    <time_frame>Visit 2 to visit 5, over a period of up to 14 weeks</time_frame>
    <description>Glucose, in mmol/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sub-study 1b: Changes in markers of glucose homeostasis after infusion of apelin in obese/overweight and T2DM, after a mixed meal challenge</measure>
    <time_frame>Visit 2 to visit 5, over a period of up to 14 weeks</time_frame>
    <description>C-peptide, in pmol/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sub-study 1b: Changes in markers of glucose homeostasis after infusion of apelin in obese/overweight and T2DM, after a mixed meal challenge</measure>
    <time_frame>Visit 2 to visit 5, over a period of up to 14 weeks</time_frame>
    <description>Glucagon, in pg/ml</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sub-study 1b: Changes in markers of glucose homeostasis after infusion of apelin in obese/overweight and T2DM, after a mixed meal challenge</measure>
    <time_frame>Visit 2 to visit 5, over a period of up to 14 weeks</time_frame>
    <description>Insulin, in pmol/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sub-study 1b: Changes in markers of glucose homeostasis after infusion of apelin in obese/overweight and T2DM, after a mixed meal challenge</measure>
    <time_frame>Visit 2 to visit 5, over a period of up to 14 weeks</time_frame>
    <description>TNF alpha, in pg/ml</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sub-study 2b: Change in forearm blood flow parameters after infusion of verapamil in the presence of L-NMMA or saline</measure>
    <time_frame>Visit 2 to visit 3, over a period of up to 10 weeks</time_frame>
    <description>Ratio,expressed as a number (no units as this is a ratio)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sub-study 2b: Change in forearm blood flow parameters after infusion of verapamil in the presence of L-NMMA or saline</measure>
    <time_frame>Visit 2 to visit 3, over a period of up to 10 weeks</time_frame>
    <description>absolute flow in the infused arm, in mg/dL/min</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sub-study 2b: Change in forearm blood flow parameters after infusion of verapamil in the presence of L-NMMA or saline</measure>
    <time_frame>Visit 2 to visit 3, over a period of up to 10 weeks</time_frame>
    <description>percentage change in the infused arm, In %</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Substudy 4: Change in cardiovascular haemodynamics after infusion of relaxin</measure>
    <time_frame>Visit 2 to visit 4, over a period of up to 8 weeks</time_frame>
    <description>Cardiac output measured by Echocardiography, in L/min</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Substudy 4: Change in cardiovascular haemodynamics after infusion of relaxin</measure>
    <time_frame>Visit 2 to visit 4, over a period of up to 8 weeks</time_frame>
    <description>Cardiac output measured by bioimpedance, in L/min</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Substudy 4: Change in cardiovascular haemodynamics after infusion of relaxin</measure>
    <time_frame>Visit 2 to visit 4, over a period of up to 8 weeks</time_frame>
    <description>Cardiac output measured by Innocor, in L/min</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Substudy 4: Change in cardiovascular haemodynamics after combined infusion of relaxin and apelin</measure>
    <time_frame>Visit 2 to visit 4, over a period of up to 8 weeks</time_frame>
    <description>Cardiac output measured by Echocardiography, in L/min</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Substudy 4: Change in cardiovascular haemodynamics after combined infusion of relaxin and apelin</measure>
    <time_frame>Visit 2 to visit 4, over a period of up to 8 weeks</time_frame>
    <description>Cardiac output measured by bioimpedance, in L/min</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Substudy 4: Change in cardiovascular haemodynamics after combined infusion of relaxin and apelin</measure>
    <time_frame>Visit 2 to visit 4, over a period of up to 8 weeks</time_frame>
    <description>Cardiac output measured by Innocor, in L/min</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Substudy 4: Change in glucose homeostasis after combined infusion of relaxin and apelin</measure>
    <time_frame>Visit 2 to visit 4, over a period of up to 8 weeks</time_frame>
    <description>Glucose, in mmol/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Substudy 4: Change in glucose homeostasis after combined infusion of relaxin and apelin</measure>
    <time_frame>Visit 2 to visit 4, over a period of up to 8 weeks</time_frame>
    <description>C-peptide, in pmol/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Substudy 4: Change in glucose homeostasis after combined infusion of relaxin and apelin</measure>
    <time_frame>Visit 2 to visit 4, over a period of up to 8 weeks</time_frame>
    <description>Glucagon, in pg/ml</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Substudy 4: Change in glucose homeostasis after combined infusion of relaxin and apelin</measure>
    <time_frame>Visit 2 to visit 4, over a period of up to 8 weeks</time_frame>
    <description>Insulin, in pmol/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Substudy 4: Change in glucose homeostasis after combined infusion of relaxin and apelin</measure>
    <time_frame>Visit 2 to visit 4, over a period of up to 8 weeks</time_frame>
    <description>TNF alpha, glucose homeostasis</description>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Anticipated">122</enrollment>
  <condition>Cardiovascular Diseases</condition>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Substudy 1A - Apelin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In sub-study 1A Healthy participants will receive systemic infusions of Apelin to establish a dose range</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Substudy 1B - Apelin/Normal Saline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In sub-study 1B , individuals with Type 2 Diabetes and individuals with increase weight will receive systemic infusions of Apelin or Normal Saline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Substudy 2A - Relaxin/Normal Saline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In sub-study 2A Healthy participants will receive intra-arterial infusions of Relaxin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Substudy 2B - Relaxin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In sub-study 2B Healthy participants will receive intra-arterial infusions of Relaxin followed by verapamil (on a background infusion of either LN Monomethyl Arginine or Normal Saline, to test effects on nitric oxide)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Substudy 3A - Relaxin with Apelin/Saline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In sub-study 3A Healthy participants will receive intra-arterial infusions of Relaxin (background infusion apelin/Normal Saline)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Substudy 3B - Apelin with Relaxin/Saline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In sub-study 3B Healthy participants will receive intra-arterial infusions of Apelin (background infusion Relaxin/Normal Saline)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Substudy 4 - Apelin and Relaxin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In sub-study 4 Healthy participants, Individuals with Type 2 Diabetes and Individuals with increase weight will receive systemic infusions of Normal saline, Relaxin, Apelin and relaxin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apelin</intervention_name>
    <description>Apelin is an endogenous peptide that activate a single G-protein couple receptor. Apelin inhibits insulin secretion, decreases glucose levels and increases insulin sensitivity.</description>
    <arm_group_label>Substudy 1A - Apelin</arm_group_label>
    <arm_group_label>Substudy 1B - Apelin/Normal Saline</arm_group_label>
    <arm_group_label>Substudy 3A - Relaxin with Apelin/Saline</arm_group_label>
    <arm_group_label>Substudy 3B - Apelin with Relaxin/Saline</arm_group_label>
    <arm_group_label>Substudy 4 - Apelin and Relaxin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Relaxin</intervention_name>
    <description>Relaxin is RLN2 encoded endogenous peptide hormone, which binds to G protein coupled receptor RXFP1.</description>
    <arm_group_label>Substudy 2A - Relaxin/Normal Saline</arm_group_label>
    <arm_group_label>Substudy 2B - Relaxin</arm_group_label>
    <arm_group_label>Substudy 3A - Relaxin with Apelin/Saline</arm_group_label>
    <arm_group_label>Substudy 3B - Apelin with Relaxin/Saline</arm_group_label>
    <arm_group_label>Substudy 4 - Apelin and Relaxin</arm_group_label>
    <other_name>RLX</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal saline</intervention_name>
    <description>Vehicle</description>
    <arm_group_label>Substudy 1B - Apelin/Normal Saline</arm_group_label>
    <arm_group_label>Substudy 2A - Relaxin/Normal Saline</arm_group_label>
    <arm_group_label>Substudy 3A - Relaxin with Apelin/Saline</arm_group_label>
    <arm_group_label>Substudy 3B - Apelin with Relaxin/Saline</arm_group_label>
    <other_name>Saline</other_name>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Verapamil</intervention_name>
    <description>NO independent challenge agent</description>
    <arm_group_label>Substudy 2B - Relaxin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>LN Monomethyl arginine</intervention_name>
    <description>Basal NO synthase inhibitor</description>
    <arm_group_label>Substudy 2B - Relaxin</arm_group_label>
    <other_name>LNMMA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Healthy participants

          -  Have given written informed consent to participate

          -  Aged 18 to 70 years inclusive

          -  Male or female

          -  Current non-smoker

          -  If female, either postmenopausal or on days 2-9 of menstrual cycle and negative
             pregnancy test performed on the day of the of visit

          -  BMI in range for studies 1 and 4: 18.5-24.9 kg/m2 with waist circumference lower than
             88 centimetres (35 inches) for women or 102 cm (40 inches) for men, and/or body fat
             level less than 32 % for women or 25% for men

          -  BMI in range for studies 2 and 3: 18.5-30.0 kg/m2 without limitations in waist
             circumference or body fat level

        Overweight/obese participants

          -  Have given written informed consent to participate

          -  Aged 18 to 70 years inclusive

          -  Male or female

          -  Current non-smoker

          -  If female, either postmenopausal or on days 2-9 of menstrual cycle and negative
             pregnancy test performed on the day of the of visit

          -  BMI in range of 25-34.9 kg/m2 (inclusive) with either waist circumference higher than
             88cm (35 inches) for women or 102 cm (40 inches) for men, and/or body fat levels in
             excess of 32% for women or 25% for men

        Participants with type 2 diabetes mellitus

          -  Have given written informed consent to participate

          -  Aged 18 to 70 years inclusive

          -  Male or female

          -  Current non-smoker

          -  If female, either postmenopausal or on days 2-9 of menstrual cycle and negative
             pregnancy test performed on the day of the of visit

          -  BMI in range of 25-34.9 kg/m2 (inclusive) with either waist circumference higher than
             88cm (35 inches) for women or 102 cm (40 inches) for men, and/or body fat levels in
             excess of 32% for women or 25% for men

          -  Documented diagnosis of Type 2 Diabetes Mellitus, either diet controlled or treated
             with oral hypoglycaemic therapy

        Exclusion Criteria:

          -  Hypersensitivity to any of the study drugs or excipients

          -  Systemic Hypertension (sustained BP &gt;160/100mmHg) or hypotension (systolic BP below 90
             mmHg)

          -  Known heart disease

          -  Implanted heart pace-maker or implantable cardioverter defibrillator (ICD)

          -  Known active malignancy

          -  Known renal failure (creatinine &gt;140Âµmol/L)

          -  Known neurological disease

          -  History of Scleroderma (Study 4 only)

          -  Current pregnancy, breast feeding

          -  Use of vasoactive medications or NSAIDS/aspirin within 24 hours of study visits

          -  Use of caffeine within 24 hours of study visits

          -  Current involvement in the active treatment phase of other research studies,
             (excluding observations/non-interventional)

          -  Second or third-degree AV block, sino-atrial block, sick sinus syndrome or sinus
             bradycardia

          -  Known HIV, hepatitis B or C

          -  Needle phobia

          -  Participants treated with formal anticoagulant therapy such as, but not limited to,
             heparin, warfarin or clopidogrel

          -  Diagnosis of Type 1 Diabetes Mellitus or current usage of insulin or other injectable
             drugs for the treatment of diabetes such as but not limited to GLP1 agonists

          -  BMI &lt;18.5

          -  Aged &lt;18 or &gt;70 years

          -  Any other clinical reason which may preclude entry in the opinion of the investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joseph Cheriyan, MBCHB, FRCP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cambridge University Hospitals NHS Foundation Trust</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Addenbrooke's Hospital</name>
      <address>
        <city>Cambridge</city>
        <state>Cambridgeshire</state>
        <zip>CB20QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joseph Cheriyan, MBChB, FRCP</last_name>
      <phone>01223 926590</phone>
      <email>jc403@medschl.cam.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Joseph Cheriyan, MBChB, FRCP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 6, 2018</study_first_submitted>
  <study_first_submitted_qc>February 22, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 28, 2018</study_first_posted>
  <last_update_submitted>May 16, 2018</last_update_submitted>
  <last_update_submitted_qc>May 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cambridge University Hospitals NHS Foundation Trust</investigator_affiliation>
    <investigator_full_name>Joseph Cheriyan, MD</investigator_full_name>
    <investigator_title>Consultant Physician &amp; Clinical Pharmacologist/Assoc Lecturer</investigator_title>
  </responsible_party>
  <keyword>Apelin</keyword>
  <keyword>Relaxin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Verapamil</mesh_term>
    <mesh_term>Methocarbamol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

